Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
3n-But and TS inhibitors acted synergistically against colorectal cancers, independently of the genetic alterations of the hCRCs.
|
11231942 |
2001 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
3R variant of thymidylate synthase 5'-untranslated enhanced region contributes to colorectal cancer risk: a meta-analysis.
|
22938428 |
2012 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.
|
15205195 |
2004 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
5-FU+GA further decreased P53, survivin and TS mRNA and protein levels in the two CRC cell lines compared with single drugs, whereas increased P53 protein levels were observed in HCT116 cells.
|
28352348 |
2017 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Colorectal cancer (CRC) resistance to fluoropyrimidines and other inhibitors of thymidylate synthase (TS) is a serious clinical problem often associated with increased intracellular levels of TS.
|
17339891 |
2007 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase (TS) is a major target in the chemotherapy of colorectal cancer and some other neoplasms.
|
11278511 |
2001 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
|
12450430 |
2001 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase pharmacogenetics in colorectal cancer.
|
12450432 |
2001 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
|
12576452 |
2003 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase (TS) is an important target for chemotherapy and increased levels are associated with resistance to colorectal cancer chemotherapy.
|
12763222 |
2003 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase (TS) is the target enzyme for 5-fluorouracil (5-FU), and TS expression may determine clinical response and survival after therapy with 5-FU in colorectal cancer.
|
14519641 |
2003 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thymidylate synthase polymorphism and microsatellite instability: association in colorectal cancer.
|
15571262 |
2004 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
|
15627889 |
2005 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
|
17047489 |
2006 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase (TS) is an essential enzyme for DNA synthesis and repair and elevated levels of TS have been identified as an important prognostic biomarker for colorectal cancer and several other common human malignancies.
|
17297449 |
2007 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
|
17330233 |
2007 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase (TS) expression levels appear to be related to response to 5-fluorouracil-(5-FU)-based chemotherapy in colorectal cancer (CRC) patients.
|
21536130 |
2011 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthetase is the major target of 5-fluorouracil (5-FU), which is widely used for the treatment of gastric cancer (GC) and colorectal cancer (CRC).
|
23645036 |
2013 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TYMS effect on lymph node metastasis in CRC might serve as a potential biomarker for LNM and a prognostic factor in CRC.
|
23810585 |
2013 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase is associated with risk of colorectal cancer but not with gastric cancer; however, heterozygous SL (2R/3R) polymorphism is associated with risk of gastric cancer; moreover, the 5' tandem repeat polymorphism of thymidylate synthase gene was an independent predictor of the clinical treatment.
|
24415354 |
2014 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer.
|
31367274 |
2019 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
|
24647007 |
2015 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A good prediction of TS mRNA levels in liver metastases can be obtained by measuring those of primary CRC, although no correlation was seen for DPD, TP and OPRT.
|
16572420 |
2006 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A group of 43 patients with colorectal carcinoma were evaluated for the 6 bp/1494 polymorphism and for intratumoral TS mRNA levels in vivo.
|
15115918 |
2004 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A large sample is required before DPYD or TYMS genotyping could be used as markers for individualized treatment of patients with colorectal cancer.
|
17417073 |
2007 |